Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic
Hepatitis B and C at EASL 2013
STRASBOURG, France -- April 8, 2013
Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical
company that develops targeted immunotherapy products to treat major unmet
medical needs in cancer and infectious diseases, today announced that
favourable pre-clinical and clinical data on two Transgene products – TG1050
and TG4040 to treat chronic hepatitis B (CHB) and chronic hepatitis C (CHC),
respectively – will be presented in oral presentations at this year’s European
Association for the Study of the Liver (EASL) Conference (Amsterdam,
Netherlands, April 24-28, 2013). The full abstracts are available at
“We are delighted to have the opportunity to present data at EASL, Europe’s
largest liver conference. TG1050 is a novel immunotherapeutic to treat CHB
that has shown very promising preclinical results and will soon be moving to
early clinical development” stated Philippe Archinard, Chairman and CEO of
Transgene. He added: “In addition to the preclinical proof-of-concept data
published in September 2012^1, we have today released supplementary
information, obtained in pre-clinical naïve and HBV murine models, on the
immunogenicity of TG1050 and its capacity to induce long-term T cell response.
This evidence further underlines our belief in the product’s potential to
become an important new first in class immunotherapeutic to treat CHB, an area
of unmet medical need.”
“TG4040 has recently completed successful phase 2 trial in patients with CHC”
stated Nathalie Adda, Chief Medical Officer of Transgene. She added:
“Following interim data published in April last year for TG4040 in combination
with PegIFNα2a and ribavirin, we report the final results of the phase 2 HCVac
trial with sustained viral response at 24 weeks (SVR24) and additional
immunogenicity, specific T-cell and humoral responses. The study has
demonstrated that pre-treatment with TG4040 has a positive impact on viral
response as shown by cEVR and SVR improvement compared to PegIFN alpha 2a and
Ribavirin alone. HCV Immunotherapy now could be explored in combination with
an IFN-free DAA regimen.”
^1 Poster Presentation of TG1050 at the International HBV Meeting in Oxford,
The oral presentations will take place on Friday, April 26 and Saturday, April
Friday, April 26, ^ Session entitled: HCV Direct Acting Antivirals (abstract
Phase 2 HCVac Study of TG4040 immunotherapeutic in combination with PegIFNα2a
and ribavirin in genotype 1 CHC treatment naïve patients: SVR24 Final Results
Oral presentation by Pr. Heiner Wedemeyer, Principal Investigator of the HCVac
study, University of Hanover, Germany
Session Time: 16:00-18:00
Saturday, April 27, Session entitled: Hepatitis B and D Experimental (abstract
A Multivalent Adenovirus-Based Immunotherapeutic for Treatment of Chronic
Hepatitis B Induces Broad, Robust and Polyfunctional T Cells in Naïve and HBV
Oral presentation by Dr. Perrine Martin, Scientific Coordinator of the
Hepatitis B Program, Department of Infectious Diseases, Transgene SA.
Session Time: 15:30-17:30
The novel immunotherapeutic product TG1050 developed by Transgene to treat
chronic infection by hepatitis B is based on a recombinant non-replicative
human adenovirus serotype 5, expressing multiple specific HBV antigens (Core,
Polymerase and Envelope) from genotype D. The product has been designed to
prime de novo and/or stimulate functional T cells expected to control the HBV
replication and to elicit viral clearance.
According to the World Health Organization’s (WHO) estimates, 350 million
people are chronic carriers (WHO, 2009) of HBV. Hepatitis B is more common in
some parts of the world than others. In China and other parts of Asia, up to
10% of the population is believed to be chronically infected. In addition to
the significant burden of disease, CHB is responsible for 1 million deaths
each year due to related complications such as liver failure, cirrhosis or
hepatocellular carcinoma (liver cancer).
Transgene’s TG4040 vaccine candidate is a recombinant vector based on the MVA
virus carrying and expressing three of the major non-structural proteins (NS3,
NS4 and NS5B) of the hepatitis C virus (HCV). The MVA vector is a highly
attenuated strain of vaccinia virus, which has been tested extensively in
humans as a vaccine against smallpox and is known to strongly stimulate innate
and adaptive immune responses to antigens.
About TG4040 Clinical Development Program
153 patients in the phase 2 HCVac study were recruited in five countries in
Europe, in the United States and in Israel, and were randomized in one control
arm (Arm A; 48 weeks of Peg-IFN/RBV) or one of the two experimental arms (Arms
B and C). In the Arm B, the TG4040 dosage (subcutaneous injections at the dose
of 10^7 pfu) was administered 6 times and Peg-IFN/RBV was given 4 weeks prior
to the initiation of TG4040. In the Arm C, the TG4040 dosage was administered
13 times and Peg-IFN/RBV was introduced 12 weeks after the initiation TG4040.
The HCVac trial investigated the efficacy and safety of these two different
schedules of TG4040 administration in combination with Peg-IFN and RBV.
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a
biopharmaceutical company. It creates, develops and manufactures targeted
immunotherapeutics for the treatment of cancers and infectious diseases.
Transgene’s products are major technological breakthroughs. They use well
tolerated viruses to indirectly or directly kill infected or cancerous cells.
Its four most advanced products have generated proof of concept data in
randomized clinical studies: in lung cancer (TG4010), liver cancer (Pexa-Vec),
hepatitis C (TG4040) and HPV-related cervical lesions (TG4001). Transgene has
concluded strategic agreements for the development of three of these products:
an option agreement with Novartis for the development of TG4010, an
in-licensing agreement with US-based Jennerex, Inc. to develop and market
Pexa-Vec and a strategic collaboration with EORTC to develop TG4001 in cancer
of the oropharynx. Transgene also has a non exclusive agreement with
Sanofi/Genzyme for its future commercial production. With 280 employees, it is
based in Strasbourg, France, and has operations in Lyon, China and the USA.
Additional information about Transgene is available at www.transgene.fr.
Transgene Forward Looking Statements
This press release contains forward-looking statements notably referring to an
anticipated future BLA filing date by Transgene. Such anticipated future BLA
filing date is based on the current plan of product development and testing.
This plan may change in the future and, as such, Transgene could be in a
position not to meet the currently anticipated development milestones,
including such BLA filing. For further information on the risks and
uncertainties involved in the testing and development of Transgene’s product
candidates, see Trangene’s Document de Référence on file with the French
Autorité des marchés financiers on its website at http://www.amffrance.org and
on Transgene’s website at www.transgene.fr .
Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405
ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél: + 33 (0)3 88 27 91 00
Philippe Archinard, +33 (0)3 88 27 91 22
Chairman & CEO
Stéphane Boissel, +33 (0)3 88 27 91 02
Executive Vice President & CFO
Elisabetta Castelli, +33 (0)3 88 27 91 21
Raimund Gabriel, +49 89 210 228 30
Shaun Brown, +44 207 148 5998
Press spacebar to pause and continue. Press esc to stop.